CD10- A New Prognostic Stromal Marker in Breast Carcinoma, It’s Utility, Limitations and Role in Breast Cancer Pathogenesis by Arun Prabhakaran, C
TITLE: CD10-  A  NEW  PROGNOSTIC  STROMAL  MARKER  IN  BREAST  
CARCINOMA,  IT’S  UTILITY,  LIMITATIONS  AND  ROLE  IN  BREAST  




Seldom  has  a  disease  evoked  more  interest  and  dreadful  fear  in  the  
common  man  like  it  has  for  cancer.  Breast  cancer  amongst  all  cancers,  
continue  to  evoke  such  responses  and  even  more  research,  especially  since  the  
treatment  involves  surgery  which  leaves  physical  and  emotional  scars  in  its  
victims. 
Breast  carcinoma  is  the  commonest  cancer  in  women.  It  is  the  leading  
cause  of  death  in  women,  with  more  than  one  million  cases  occuring  
worldwide  annually.  Breast  cancer  represents  an  important  public  health  issue,  
having  a  high  occurence  worldwide,  with  an  obvious  increasing  tendency. 
The  Edwin  Smith  Surgical  Papyrus  is  having  the  first  reference  to  breast  
cancer.  This  surgical  text,  described  in  hieratic  script,  is  the  incomplete  copy  
of  an  original  record  that  dates  back  to  the  pyramid  age  of  Egypt  (3000-
2500BC) . 
The  incidence  of  cancer  has  been  on  rise  worldwide.  Breast  cancer  
incidence  accounts  for  16%  of  all  breast  cancers,  as  per  the  WHO  cancer  
control  and  prevention  program.  It  is  calculated  that  519  women  died  owing  to  
breast  malignancy  in  2004 .  Inspite  of  the  fact,  breast  cancer  is  thought  to  be  
a  disease  of  the  developed  world,  majority  of      breast  cancer  mortality  (69%),  
is  in  developing  countries.  Hence  breast  cancer  has  emerged  to  be  one  of  the  
leading  cancer  killers  amongst  women  worldwide. 
Over  the  last  few  decades  there  have  been  better  advances  in  breast  
cancer.  Early  detection    and  skill full    treatment  has  lead  to  a  significant  
decline    in  breast  cancer  deaths.    It  has  also  made  improved  outcome  for  
women  living  with  the  disease.  Breast  cancer  is  no  longer  seen  as  single  
disease  but  rather  a  multifaceted  disease  consisting  of  diverse  biological  
subtypes  with  distinct  natural  history.  Breast  cancer  presents  as  a  varied  
spectrum  of  clinical,  pathological  and  molecular  features  with  diverse  prognostic  
and  therapeutic  implications. 
Estrogen  is  the  steroid  hormone,  responsible  for  development  and  
maturation  of  primary  and  secondary  sexual  characteristics  in  females.  Estrogen  
has  an  important  role  in  pathogenesis  and  development  of  breast  cancer . 
Estrogen  receptor  is  an  intracellular  protein  molecule.    They  are  targets  
for  estrogen  action.  Estrogen  receptor  normally  resides  in  cell  nucleus,  along  
with  DNA  molecules.  Estrogen  receptor  alpha  gene  polymorphism  leads  to  
alteration  in  estrogen  receptor  function  in  breast  cancer . 
 
AIMS AND OBJECTIVES 
• To  study  the  stromal  expression  of  CD10  in  breast  carcinoma   
• To  study  relationship  with  certain  prognostic  factors  like, 
 1.  Age, 2.  Nottingham’s  grade and 3.  ER,  PR,  HER2neu 
• To  study  the  role  of  stroma  in  the  pathogenesis  of  breast  cancer 
• To  study  the  role  of  CD10  in  triple  negative  cases 
MATERIALS AND METHODS 
 A total of 75 cases of breast cancer were included in the study. Representative 
sections were taken and hematoxylin and eosin staining was done. 
Immunohistochemistry was performed with ER, PR, Her2neu and CD10. Stromal 
expression of CD10 (>10% stromal positivity was considered positive) in invasive 
breast carcinoma was noted and was statistically analyzed with different known 
prognostic markers of breast carcinoma. 
RESULTS 
 Stromal expression of CD10 was found to be significantly associated with 
increasing tumor grade (P = <0.0001), ER negativity (P = <0.0001), PR negativity (P 
= <0.0001), Her2neu positivity (P = <0.0001) and with triple negative cases. No 




  The  stromal  expression  of  CD10  has  significant  correlation  
with  higher  histological  grade  (Grade  3),  ER  negativity,  PR  negativity  
and  HER2neu  positivity  and  triple  negativity 
 There  is  no  correlation  between  CD10  expression  and  age  of  the  
patient 
 The  intensity  of  CD10  positivity  also  increased  with  increasing  
histological  grade,  hormonal  receptor  negativity,  HER2neu  positivity  and  
triple  negative  cases 
 There  is  wide  expression  of  CD10  in  desmoplastic  stroma  of  
breast  carcinoma  and  negative  immunoreactivity  in  stromal  cells  of  normal  
breast 
 This  study  highlights  the  role  of  stromal  CD10  expression  in  
predicting  tumor  response  and  prognosis  and  therefore  CD10  could  be  
included  as  a  routine  marker  along  with  other  markers  for  invasive  
carcinoma  breast  before  giving  chemotherapy 
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